View filters (6 in use)

Updating results

69 results

Sort: Relevance | Date

Insect bites and stings: antimicrobial prescribing: draft guidance consultation

We are listening to your views on this antimicrobial prescribing guideline. Comments close 20 December 2019.

NICE guideline In consultation

Meningitis (bacterial) and meningococcal septicaemia: recognition, diagnosis and management: draft scope consultation

We are listening to your views on this NICE guideline. Comments close 24 December 2019.

NICE guideline In consultation

Perioperative care in adults: draft guidance consultation

We are listening to your views on this NICE guideline. Comments close 24 January 2020.

NICE guideline In consultation

Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (2019): draft guidance consultation

We are listening to your views on this NICE guideline. Comments close 24 December 2019.

NICE guideline In consultation

Selective internal radiation therapies for treating hepatocellular carcinoma ID1276: appraisal consultation

We are listening to your views on this technology appraisal guidance. Comments close 08 January 2020.

Technology appraisal guidance In consultation

Tafamidis for treating transthyretin amyloid cardiomyopathy [ID1531]

Proposed [GID-TA10451] Expected publication date: 10 June 2020

Technology appraisal guidance Proposed

Dupilumab for treating chronic rhinosinusitis with nasal polyps ID1179

Proposed [GID-TA10450] Expected publication date: TBC

Technology appraisal guidance Proposed

Semaglutide for treating type 2 diabetes (ID1450)

Proposed [GID-TA10438] Expected publication date: TBC

Technology appraisal guidance Proposed

Rivaroxaban for treating chronic heart failure [ID1462]

Proposed [GID-TA10393] Expected publication date: TBC

Technology appraisal guidance Proposed

Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer ID1429

Proposed [GID-TA10512] Expected publication date: TBC

Technology appraisal guidance Proposed

Abicipar pegol for treating wet age-related macular degeneration ID1533

Proposed [GID-TA10511] Expected publication date: TBC

Technology appraisal guidance Proposed

Angiotensin II for treating vasopressor-resistant hypotension caused by distributive shock ID1588

Proposed [GID-TA10507] Expected publication date: TBC

Technology appraisal guidance Proposed

Voxelotor for treating sickle cell disease [ID1403]

Proposed [GID-TA10505] Expected publication date: TBC

Technology appraisal guidance Proposed

Avelumab for treating metastatic Merkel cell carcinoma (CDF Review of TA517) ID1617

Proposed [GID-TA10545] Expected publication date: 19 September 2020

Technology appraisal guidance Proposed

Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF Review TA600) ID1683

Proposed [GID-TA10537] Expected publication date: 12 August 2020

Technology appraisal guidance Proposed

Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) ID1585

Proposed [GID-TA10538] Expected publication date: 12 August 2020

Technology appraisal guidance Proposed

Ranibizumab for treating diabetic retinopathy [ID1592]

Proposed [GID-TA10521] Expected publication date: TBC

Technology appraisal guidance Proposed

Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587

Proposed [GID-TA10519] Expected publication date: TBC

Technology appraisal guidance Proposed

Esketamine for treating major depressive disorder in adults at imminent risk for suicide ID1604

Proposed [GID-TA10518] Expected publication date: TBC

Technology appraisal guidance Proposed

Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]

Proposed [GID-TA10522] Expected publication date: TBC

Technology appraisal guidance Proposed

Midostaurin for treating advanced systemic mastocytosis ID1573

Proposed [GID-TA10503] Expected publication date: TBC

Technology appraisal guidance Proposed

Tocilizumab for treating systemic sclerosis (ID1396)

Proposed [GID-TA10346] Expected publication date: TBC

Technology appraisal guidance Proposed

Pegvaliase for treating phenylketonuria [ID1110]

Proposed [GID-TA10345] Expected publication date: TBC

Technology appraisal guidance Proposed

STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)

Proposed [GID-TA10279] Expected publication date: TBC

Technology appraisal guidance Proposed

Mepolizumab for treating chronic obstructive pulmonary disease (ID1237)

Proposed [GID-TA10239] Expected publication date: TBC

Technology appraisal guidance Proposed

Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis ID1178

Proposed [GID-TA10199] Expected publication date: TBC

Technology appraisal guidance Proposed

Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154

Proposed [GID-TA10198] Expected publication date: TBC

Technology appraisal guidance Proposed

Brentuximab vedotin for untreated CD30-positive peripheral T-cell lymphoma ID1586

Proposed [GID-TA10514] Expected publication date: 12 August 2020

Technology appraisal guidance Proposed

Secukinumab for treating moderate to severe plaque psoriasis in children and young people [ID1669]

Proposed [GID-TA10554] Expected publication date: TBC

Technology appraisal guidance Proposed

Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]

Proposed [GID-TA10555] Expected publication date: TBC

Technology appraisal guidance Proposed

Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs [ID1658]

Proposed [GID-TA10561] Expected publication date: TBC

Technology appraisal guidance Proposed

Ponesimod for treating relapsing multiple sclerosis [ID1393]

Proposed [GID-TA10556] Expected publication date: TBC

Technology appraisal guidance Proposed

Ofatumumab for treating relapsing multiple sclerosis [ID1677]

Proposed [GID-TA10557] Expected publication date: TBC

Technology appraisal guidance Proposed

Omalizumab for treating chronic rhinosinusitis with nasal polyps [ID1650]

Proposed [GID-TA10558] Expected publication date: TBC

Technology appraisal guidance Proposed

Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)

Proposed [GID-TA10306] Expected publication date: TBC

Technology appraisal guidance Proposed

Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]

Proposed [GID-TA10332] Expected publication date: TBC

Technology appraisal guidance Proposed

Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]

Proposed [GID-TA10336] Expected publication date: TBC

Technology appraisal guidance Proposed

Intravenous zanamivir for treating influenza in hospital [ID1196]

Proposed [GID-TA10298] Expected publication date: TBC

Technology appraisal guidance Proposed

Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery [ID1149]

Proposed [GID-TA10297] Expected publication date: TBC

Technology appraisal guidance Proposed

Esketamine for treatment-resistant depression (ID1414)

Proposed [GID-TA10371] Expected publication date: 18 March 2020

Technology appraisal guidance Proposed

Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy [ID1410]

Proposed [GID-TA10391] Expected publication date: TBC

Technology appraisal guidance Proposed

Upadacitinib for treating moderate to severe rheumatoid arthritis [ID1400]

Proposed [GID-TA10389] Expected publication date: 18 March 2020

Technology appraisal guidance Proposed

Fostamatinib for treating persistent or chronic immune thrombocytopenia [ID1087]

Proposed [GID-TA10387] Expected publication date: TBC

Technology appraisal guidance Proposed

Pitolisant hydrochloride for treating obstructive sleep apnoea ID1065

Proposed [GID-TA10385] Expected publication date: TBC

Technology appraisal guidance Proposed

Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery (ID1105)

Proposed [GID-TA10348] Expected publication date: TBC

Technology appraisal guidance Proposed

Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]

Proposed [GID-TA10470] Expected publication date: 24 March 2021

Technology appraisal guidance Proposed

Baricitinib for treating moderate to severe atopic dermatitis [ID1622]

Proposed [GID-TA10562] Expected publication date: TBC

Technology appraisal guidance Proposed

Liraglutide for managing obesity in people aged 12 to 17 [ID1630]

Proposed [GID-TA10563] Expected publication date: TBC

Technology appraisal guidance Proposed

Baloxavir marboxil for treating influenza [ID1537]

Proposed [GID-TA10559] Expected publication date: TBC

Technology appraisal guidance Proposed

Dapagliflozin for treating heart failure with reduced ejection fraction [ID1656]

Proposed [GID-TA10560] Expected publication date: TBC

Technology appraisal guidance Proposed